글로벌 비만 후 저혈당증(PBH) 치료 시장 - 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 비만 후 저혈당(PBH) 치료 시장

비만 후 저혈당(PBH) 치료 시장은 2021년부터 2028년까지의 예측 기간 동안 7.7%의 시장 성장을 보일 것으로 예상됩니다. 비만 후 저혈당(PBH) 치료 시장에 대한 Data Bridge Market Research 보고서는 예측 기간 동안 만연할 것으로 예상되는 다양한 요인에 대한 분석과 통찰력을 제공하고 시장 성장에 미치는 영향을 제공합니다. 전 세계적으로 비만 유병률이 증가함에 따라 비만 후 저혈당(PBH) 치료 시장 성장이 가속화되고 있습니다.

비만 후 저혈당증은 일반적으로 혈장 포도당 수치가 54mg/dL 미만으로 낮은 신경당 감소증 상태를 말하며, 환자가 비만 수술을 받았을 때 발생합니다. 비만 수술은 체중 감량에 도움이 되는 수술로 정의됩니다. 이 신경당 감소증 상태는 과도한 글루카곤 유사 펩타이드-1(GLP-1) 생성으로 인해 발생하는 비만 수술의 심각한 합병증 중 하나로 간주되며, 이는 고인슐린혈증성 저혈당증을 초래합니다.

전 세계적으로 비만 수술의 수가 증가한 것은 비만 후 저혈당(PBH) 치료 시장 성장을 견인하는 주요 요인 중 하나입니다. 규제 당국의 특별 지정 증가와 제조업체 간의 인수 전략 및 회사 협력의 증가율은 시장 성장을 가속화합니다. 비만 및 관련 합병증 치료를 위한 비만 수술 에 대한 수요 증가 와 인구의 신체 의식 증가는 시장 성장에 더욱 영향을 미칩니다. 또한, 의료 인프라의 발전, 비만 인구의 증가, 건강에 해로운 삶의 선택의 채택은 비만 후 저혈당(PBH) 치료 시장에 긍정적인 영향을 미칩니다. 나아가, 새로운 개입의 개발은 2021년에서 2028년까지의 예측 기간 동안 시장 참여자에게 수익성 있는 기회를 확대합니다.

On the other hand, high cost associated with the treatment of post-bariatric hypoglycemia (PBH) and failure of clinical trials during the development stage are expected to obstruct the market growth. Lack of trained medical personnels and stringent safety regulations are projected to challenge the post-bariatric hypoglycemia (PBH) treatment market in the forecast period of 2021-2028.

This post-bariatric hypoglycemia (PBH) treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on post-bariatric hypoglycemia (PBH) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Post-Bariatric Hypoglycemia (PBH) Treatment Market Scope and Market Size

The post-bariatric hypoglycemia (PBH) treatment market is segmented on the basis of drug class, mode of administration, distribution channel, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of drug class, the post-bariatric hypoglycemia (PBH) treatment market is segmented into glucosidase inhibitor, somatostatin agonist, calcium ion influx inhibitor and others.
• On the basis of mode of administration, the post-bariatric hypoglycemia (PBH) treatment market is segmented into injectable, oral and others.
• On the basis of distribution channel, the post-bariatric hypoglycemia (PBH) treatment market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
• On the basis of end user, the post-bariatric hypoglycemia (PBH) treatment market is segmented into hospitals, homecare, specialty clinics and others.

Global Post-Bariatric Hypoglycemia (PBH) Treatment Market Country Level Analysis

The post-bariatric hypoglycemia (PBH) treatment market is analyzed and market size information is provided by country, drug class, mode of administration, distribution channel and end user as referenced above.

The countries covered in the global post-bariatric hypoglycemia (PBH) treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the post-bariatric hypoglycemia (PBH) treatment market due to the high prevalence of obesity within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2021 to 2028 because of the high population in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The post-bariatric hypoglycemia (PBH) treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Post-Bariatric Hypoglycemia (PBH) Treatment Market Share Analysis

The post-bariatric hypoglycemia (PBH) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related twin-twin transfusion syndrome treatment market.

비만 후 저혈당(PBH) 치료 시장 보고서에서 다루는 주요 기업으로는 XOMA, Zealand Pharma A/S, Eiger BioPharmaceuticals, Xeris Pharmaceuticals, Inc, Bayer, Emcure Pharmaceuticals, Virtus, Mylan NV, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Pfizer Inc, Exela Pharma Sciences, LLC, Novartis AG, WOCKHARDT, Fresenius Kabi AG, Sun Pharmaceutical Industries Limited, Micro Labs Ltd 등이 있으며, 국내 및 글로벌 기업도 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA), 남미에 대해 각각 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-46385